Breakthrough in cancer research: a team of scientists has found a way to break down, the resistance of neuroendocrine pancreatic cancer to immunotherapy, resulting in increased survival rates in mice. Combining PD1-IL2v with anti-PD-L1 proved to be more effective than using just one of the molecules. The study published in Immunity results from a collaboration between scientists at EPFL, Ludwig Institute for Cancer Research, CHUV and Roche.
